SUMMARY
Voltaren Ophthalmic (diclofenac sodium ophthalmic solution) 0.1% solution is a sterile, topical, non-steroidal, anti-inflammatory product for ophthalmic use.
Voltaren Ophthalmic is indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction and for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery.
|
NEWS HIGHLIGHTS
Published Studies Related to Voltaren Ophthalmic (Diclofenac Ophthalmic)
Effect of preemptive topical diclofenac on postoperative pain relief after photorefractive keratectomy. [2011.04]
PURPOSE: To assess the prophylactic effect of preoperative application of topical diclofenac on postoperative pain control in patients having photorefractive keratectomy (PRK). SETTING: Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran. DESIGN: Randomized masked clinical trial... CONCLUSION: Administration of a single drop of topical diclofenac 0.1% 2 hours before PRK seemed to increase the efficacy of postoperative pain management in a clinically and statistically significant manner. FINANCIAL DISCLOSURE: No author has a financial or proprietary interest in any material or method mentioned. Copyright (c) 2011 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.
The influence of topical diclofenac sodium on the ocular hypotensive effect of latanoprost in glaucoma patients. [2011.04]
PURPOSE: To evaluate the effect of diclofenac sodium 0.1% on reducing intraocular pressure (IOP) by latanoprost 0.005% in glaucoma patients... CONCLUSIONS: Topical diclofenac sodium may interfere with the IOP lowering effect of latanoprost in glaucoma patients; therefore this interference should be noted in coadministration of these drugs.
Management of pain with diclofenac after femtosecond-assisted laser in situ keratomileusis. [2011.03]
PURPOSE: To evaluate the safety and efficacy of topical diclofenac sodium 0.1% after femtosecond laser-assisted laser in situ keratomileusis (LASIK). SETTING: W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, USA. DESIGN: Clinical trial... CONCLUSION: Pain after femtosecond laser-assisted LASIK was mild and was reduced with a single dose of topical diclofenac sodium 0.1% given immediately after surgery. Copyright (c) 2011 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.
Effect of preemptive topical diclofenac on postoperative pain relief after
photorefractive keratectomy. [2011]
DESIGN: Randomized masked clinical trial... CONCLUSION: Administration of a single drop of topical diclofenac 0.1% 2 hours
Management of pain with diclofenac after femtosecond-assisted laser in situ
keratomileusis. [2011]
DESIGN: Clinical trial... CONCLUSION: Pain after femtosecond laser-assisted LASIK was mild and was reduced
Clinical Trials Related to Voltaren Ophthalmic (Diclofenac Ophthalmic)
Study to Compare the Pharmacokinetics of IV Diclofenac Sodium (2 Doses)Versus Oral Diclofenac Potassium [Completed]
The purpose of this study is to assess the pharmacokinetic parameters of intravenous
diclofenac sodium (DIC075V) 18. 75 mg and 37. 5 mg following single- and multiple-dose
administration, as compared to oral diclofenac potassium (Cataflam® 50 mg), the approved
reference product.
Assess Platelet Function and Safety After Administration of Injectable Diclofenac Compared to Ketorolac and Aspirin in Adult Male Volunteers [Completed]
This study will assess platelet function and safety in healthy male volunteers following
doses of intravenous diclofenac compared to cataflam, intravenous ketorolac and aspirin.
A Study Comparing Diclofenac Sodium Gel 3% to Solaraze� Gel 3% in the Treatment of Actinic Keratosis [Recruiting]
The objective of this study is to compare the relative efficacy and safety of the test
formulation diclofenac sodium gel 3% (Taro Pharmaceuticals Inc.) to the marketed formulation
Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms) in the treatment of actinic keratosis.
Both the test and reference formulations will also be compared to a placebo formulation to
test for superiority.
A Clinical Study in Healthy Male Volunteers to Compare the Bioequivalence of Fixed Dose Combination of Eperisone Hydrochloride 50mg Plus Diclofenac Sodium 50mg as Capsule With Eperisone Hydrochloride 50mg and Diclofenac Sodium 50mg Tablets Under Fasting Conditions [Recruiting]
The primary objective of this study is to compare the bioavailabilities of a single fixed
dose combination of eperisone 50 mg plus diclofenac 50 mg capsules with the
bioavailabilities of eperisone 50 mg tablets and diclofenac 50 mg tablets in healthy human
adult male subjects under fasting conditions.
Effects of Pennsaid on Clinical Neuropathic Pain [Recruiting]
The purpose of this study is to see if the drug Pennsaid (Diclofenac) can help reduce pain
felt by people with chronic nerve pain. The drug will be used 2-4 times each day for 2
weeks.
The U. S. Food and Drug Administration (FDA) has approved Pennsaid to treat osteoarthritis
(bone pain), but the FDA has not approved Pennsaid to treat neuropathic (nerve) pain.
The research study will compare Pennsaid to placebo.
|
